Search results
Results from the Tech24 Deals Content Network
There are two monoclonal antibody treatments for Ebola virus disease, Inmazeb™ and Ebanga™. Monoclonal antibodies work like your body’s natural antibodies and help fight off the infection while your body builds its own defenses.
WHO has made strong recommendations for the use of two monoclonal antibody treatments in treating Ebola: mAb114 (Ansuvimab; Ebanga) and REGN-EB3 (Inmazeb). The average Ebola case fatality rate is around 50%.
Today, the FDA approved Inmazeb, a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients.
Two treatments are approved by the U.S. Food and Drug Administration (FDA) to treat Ebola disease caused by Ebola virus (species Zaire orthoebolavirus). Inmazeb ® is a combination of three monoclonal antibodies and Ebanga ® is a single monoclonal antibody.
The World Health Organization (WHO) has published its first guideline for Ebola virus disease therapeutics, with new strong recommendations for the use of two monoclonal antibodies. WHO calls on the global community to increase access to these lifesaving medicines.
Researchers Have Finally Found an Effective Treatment for Ebola. Two treatments have been found to reliably help patients resist the deadly virus—just nine months after a clinical trial...
The FDA has approved the first treatment for Ebola. Lab-made antibodies marshal an immune response and curb the virus’s ability to infect cells. A United Nations peacekeeper has his shoes...
The U.S. Food and Drug Administration approved Ebanga (Ansuvimab-zykl), a human monoclonal antibody, for the treatment for Zaire ebolavirus (Ebolavirus) infection in adults and children....
The investigational antiviral agent GS-5734, also known as remdesivir, is being developed by Gilead as a treatment for Ebola virus disease. NIAID is studying its ability to clear Ebola virus RNA from the semen of Ebola survivors in a study in Liberia known as PREVAIL 4 .
The UN agency also provided recommendations regarding therapeutics that should not be used as treatments, which include ZMapp and remdesivir. The new guidance, published simultaneously in...